4D Molecular Therapeutics, Inc.: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.

Reading these values

This selected numerical history matches Diluted earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Selected filing history

Related financial histories

• 4D Molecular Therapeutics, Inc.: total assets
• 4D Molecular Therapeutics, Inc.: total liabilities
• 4D Molecular Therapeutics, Inc.: stockholders equity
• 4D Molecular Therapeutics, Inc.: cash and cash equivalents
• 4D Molecular Therapeutics, Inc.: net income or loss
• 4D Molecular Therapeutics, Inc.: operating cash flow
• 4D Molecular Therapeutics, Inc.: capital expenditure payments
• 4D Molecular Therapeutics, Inc.: revenue
• 4D Molecular Therapeutics, Inc.: contract revenue excluding tax
• 4D Molecular Therapeutics, Inc.: financing cash flow
• 4D Molecular Therapeutics, Inc.: investing cash flow
• 4D Molecular Therapeutics, Inc.: retained earnings or deficit
• 4D Molecular Therapeutics, Inc.: basic weighted-average shares
• 4D Molecular Therapeutics, Inc.: diluted weighted-average shares
• 4D Molecular Therapeutics, Inc.: diluted earnings per share
• 4D Molecular Therapeutics, Inc.: net property, plant and equipment
• 4D Molecular Therapeutics, Inc.: share-based compensation expense
• 4D Molecular Therapeutics, Inc.: operating income or loss
• 4D Molecular Therapeutics, Inc.: current assets
• 4D Molecular Therapeutics, Inc.: current liabilities
• 4D Molecular Therapeutics, Inc.: current accounts payable
• 4D Molecular Therapeutics, Inc.: net current accounts receivable
• 4D Molecular Therapeutics, Inc.: operating expenses

Inspect the source

Entity

4D Molecular Therapeutics, Inc. / CIK 0001650648

Captured

2026-09-21T17:21:52.569Z

SEC response SHA-256

e13317843a7e5752807cc6e3a08cd101e2ba7eb8e534589a5e1ddf9a838c1244

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001650648.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))